Alexander David Mendelow

Dr. Alexander David Mendelow

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2000 in Physiological Measurement
Verified
Journal Article
Closed access
PDF file
KBK Banister
K Banister
ICI R Chambers
I R Chambers
MSM S Siddique
M S Siddique
Helder Miguel FernandesHelder Miguel Fernandes
Helder Miguel Fernandes
AMAlexander David Mendelow
Alexander David Mendelow
The aim of this study was to determine the in vivo accuracy and reliability of intracranial pressure (ICP) measurement using the Codman MicroSensor by comparison with the Camino ICP transducer and associated clinical and radiological information. Paired ICP readings were recorded every minute in 17 patients. A total of 56,790 validated paired measurements were obtained over a wide range of ICP values (- 16 mm Hg to 114 mm Hg). Recording periods ranged from 3 hours to 6 days (median 41 hours). In 11 patients the MicroSensor and Camino readings were in good agreement. Paired readings were within 10 mmHg for 99% of the recording time and both readings were compatible with clinical intracranial events at all times (in one case it was not possible to verify the clinical information). In six patients large differences occurred between transducer readings (> 10 mm Hg apart for 41% of the recording period). In one case, either reading could have been compatible with intracranial clinical events. In two cases, although both readings were comparable, Camino readings were more consistent with clinical and radiological findings. In three cases, the MicroSensor readings were inconsistent with the clinical condition of the patients whereas the Camino readings were compatible. These results suggest that, during routine clinical use in our department, the MicroSensor provided misleading information in 18% of our patients and thus is not sufficiently reliable for routine use in the detection of adverse clinical events.

1 March 1992 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Open access
PDF file
DCD C Crabbe
D C Crabbe
AMAlexander David Mendelow
Alexander David Mendelow
PPP Pharoh
P Pharoh
DLD M Large
D M Large
GIG K Ions
G K Ions

1 January 2021 in Journal of Physical Therapy Science
Verified
Journal Article
Open access
PDF file
AMAlexander David Mendelow
Alexander David Mendelow
BGBarbara A. Gregson
Barbara A. Gregson
PMPatrick Mitchell
Patrick Mitchell
ISIan Schofield
Ian Schofield
MPManjunath Prasad
Manjunath Prasad
GHGerard Hargreaves
Gerard Hargreaves
[Purpose] We have previously shown inversion therapy to be effective in a small prospective randomised controlled trial of patients with lumbar disc protrusions. Our purpose now was to measure symptoms and to compare the surgery rate following inversion for 85 participants with the surgery rate in 3 control groups. [Participants and Methods] Each of the 85 inverted participants acted as their own control for the “symptomatic” part of the study. In the “Need for surgery” part of the study, one control group was made up of similar patients with leg pain and sciatica who were referred to the same clinic in the same year. Two additional control groups were examined: the original control group from the pilot trial and the lumbar disc surgery waiting list patients. [Results] Inversion therapy relieved symptoms: there were improvements in the Visual Analogue Score, Roland Morris and Oswestry Disease indices and Health Utility Score compared with their pre-treatment status. Also, the 2 year surgery rate in the inversion participants in the registry (21%) was significantly lower than in the matched control group (39% at two years and 43% at four years). It was also lower than the surgery rate in the other 2 control groups. [Conclusion] Inversion therapy relieved symptoms and avoided surgery.

1 January 2000
Verified
Book Chapter
Closed access
PDF file
JNJ. J. Nissen
J. J. Nissen
DMD. Mantle
D. Mantle
ABA. Blackburn
A. Blackburn
JBJarrod Barnes
Jarrod Barnes
TWT. Wooldridge
T. Wooldridge
AMAlexander David Mendelow
Alexander David Mendelow

Verified
Journal Article
Open access
PDF file
DMDavid Mantle
David Mantle
MDMollie Dewsbury
Mollie Dewsbury
AMAlexander David Mendelow
Alexander David Mendelow
Iain HargreavesIain Hargreaves
Iain Hargreaves
The incidence of morbidity and mortality in patients who have suffered traumatic brain injury (TBI) is such that novel therapeutic strategies are currently required. There is good evidence that ischaemia is the primary, and sometimes the secondary, cause of brain damage in TBI. This ischaemia may lead to mitochondrial dysfunction, with associated oxidative stress and inflammation, in the pathogenesis of brain injury following head trauma. This, in turn, provides a rationale for the use of supplemental coenzyme Q10 (CoQ10) in the management of TBI, given its key roles in normal mitochondrial function and as an antioxidant and anti-inflammatory agent. In this article, we, therefore, review the use of supplemental CoQ10 in animal models of TBI and its potential application in the management of TBI patients. The problem of blood–brain barrier access is discussed, and how this might be circumvented via the use of an intranasal route to provide direct access of CoQ10 to the brain. In addition, there is evidence that TBI patients have an increased risk of developing cardiac dysfunction and that this may be mediated by aberrant immune action. Given the role of CoQ10 in promoting normal cardiac function and normal immune function, the administration of CoQ10 to prevent cardiovascular complications may improve outcomes in TBI patients.

22 June 2015 in British Journal Of Neurosurgery
Verified
Journal Article
Closed access
PDF file
RFRichard Francis
Richard Francis
BGBarbara A. Gregson
Barbara A. Gregson
AMAlexander David Mendelow
Alexander David Mendelow
ERElise Rowan
Elise Rowan
F(for the STITCH(Trauma) investigators (Appendix)
for the STITCH(Trauma) investigators (Appendix)
Characteristics of traumatic intracerebral haemorrhage: An assessment of screening logs from the STITCH(Trauma) Trial. . ???aop.label???. doi: 10.3109/02688697.2015.1054349